Germany · Delayed Price · Currency is EUR PDS Biotechnology Company Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies.
The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.
In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.
Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season.
It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH.
PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 2005 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 24 |
| CEO | Frank Bedu-Addo |
Contact Details
Address: 303A College Road East Princeton, Delaware 08540 United States | |
| Phone | 800 208 3343 |
| Website | pdsbiotech.com |
Stock Details
| Ticker Symbol | EU6 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Frank Bedu-Addo | Chief Executive Officer |
| Lars Boesgaard | Chief Financial Officer |
| Stephan Toutain | Chief Operating Officer |